Impact on Medical Cost, Cumulative Survival, and Cost-Effectiveness of Adding Rituximab to First-Line Chemotherapy for Follicular Lymphoma in Elderly Patients: An Observational Cohort Study Based on SEER-Medicare

Impact on Medical Cost, Cumulative Survival, and Cost-Effectiveness of Adding Rituximab to First-Line Chemotherapy for Follicular Lymphoma in Elderly Patients: An Observational Cohort Study Based on SEER-Medicare

Rituximab improves survival in follicular lymphoma (FL), but is considerably more expensive than conventional chemotherapy. We estimated the total direct medical costs, cumulative survival, and cost-effectiveness of adding rituximab to first-line chemotherapy for FL, based on a single source of data...

Full description

Bibliographic Details
Main Authors:	Robert I. Griffiths, Michelle L. Gleeson, Joseph Mikhael, Mark D. Danese
Format:	Article
Language:	English
Published:	Hindawi Limited 2012-01-01
Series:	Journal of Cancer Epidemiology
Online Access:	http://dx.doi.org/10.1155/2012/978391

Similar Items

Chemotherapy treatments, costs of care, and survival for patients diagnosed with small cell lung cancer: A SEER‐Medicare study
by: Changxia Shao, et al.
Published: (2019-12-01)

Epidemiology and outcomes of previously undiagnosed diabetes in older women with breast cancer: an observational cohort study based on SEER-Medicare
by: Griffiths Robert I, et al.
Published: (2012-12-01)

Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma
by: Dawson, K., et al.
Published: (2021)

Maintenance rituximab in Veterans with follicular lymphoma
by: Ahmad S. Halwani, et al.
Published: (2020-10-01)

Hepatocellular Carcinoma Survival by Etiology: A SEER‐Medicare Database Analysis
by: Gagandeep Brar, et al.
Published: (2020-10-01)

Obinutuzumab Plus Chemotherapy Compared with Rituximab Plus Chemotherapy in Previously Untreated Italian Patients with Advanced Follicular Lymphoma at Intermediate–High Risk: A Cost-Effectiveness Analysis
by: Bellone M, et al.
Published: (2021-07-01)

Adding rituximab to chemotherapy for diffuse large B-cell lymphoma patients in Indonesia: a cost utility and budget impact analysis
by: Armansyah, A., et al.
Published: (2022)

Rituximab maintenance therapy of follicular lymphoma in clinical practice
by: Ulrich Dührsen, et al.
Published: (2018-07-01)

Survival impact and toxicity of metformin in head and neck cancer: An analysis of the SEER-Medicare dataset
by: Amini, A., et al.
Published: (2018)

Rituximab Maintenance Strategy in Advanced Follicular Lymphoma: Facts and Controversies
by: Martina Bogeljić Patekar, et al.
Published: (2017-01-01)

Critical appraisal of rituximab in the maintenance treatment of advanced follicular lymphoma
by: Aguiar-Bujanda D, et al.
Published: (2015-10-01)

Cost-effectiveness Analysis of Rituximab Maintenance Treatment in Patients With Follicular Lymphoma who Respond to First Line Induction Therapy in Portugal
by: Susana Carvalho, et al.
Published: (2016-01-01)

Racial differences in treatment and survival in older patients with diffuse large B-cell lymphoma (DLBCL)
by: Gleeson Michelle, et al.
Published: (2010-11-01)

Real world data on follicular lymphoma patients treated by rituximab-containing immunochemotherapy and rituximab maintenance
by: Hee Kyung Kim, et al.
Published: (2020-01-01)

Rituximab With Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma
by: Klaus Herfarth, et al.
Published: (2018-12-01)

Rituximab in the treatment of follicular lymphoma: the future of biosimilars in the evolving therapeutic landscape
by: Subramanian J, et al.
Published: (2017-04-01)

Comparative Cost Analysis Of Intravenous And Subcutaneous Administration Of Rituximab In Lymphoma Patients
by: Delgado Sánchez O, et al.
Published: (2019-11-01)

Lenalidomide plus rituximab Vs rituximab alone in relapsed or refractory indolent lymphoma: A cost‐effectiveness analysis
by: Peng‐Fei Zhang, et al.
Published: (2020-08-01)

Survival outcomes in an older US population with advanced melanoma and central nervous system metastases: SEER‐Medicare analysis
by: Natalia Sadetsky, et al.
Published: (2020-09-01)

The association of statin use after cancer diagnosis with survival in pancreatic cancer patients: a SEER-medicare analysis.
by: Christie Y Jeon, et al.
Published: (2015-01-01)

Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial
by: Zinzani Pier, et al.
Published: (2012-10-01)

Systemic and Intra-Nodal Activation of NK Cells After Rituximab Monotherapy for Follicular Lymphoma
by: Monika Enqvist, et al.
Published: (2019-09-01)

Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma
by: A Boland, et al.
Published: (2009-09-01)

Rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma
by: Y Dundar, et al.
Published: (2009-06-01)

Human herpesvirus-6 pneumonitis in a patient with follicular lymphoma following immunochemotherapy with rituximab
by: Kuwahara-Ota S, et al.
Published: (2018-05-01)

An Overview of Lenalidomide in Combination with Rituximab for the Treatment of Adult Patients with Follicular Lymphoma: The Evidence to Date
by: Yilmaz U, et al.
Published: (2021-09-01)

Disaster impacts on cost and utilization of Medicare
by: Nathanael Rosenheim, et al.
Published: (2018-02-01)

Is expanding Medicare coverage cost-effective?
by: Muennig Peter, et al.
Published: (2005-03-01)

Correction: The Association of Statin Use after Cancer Diagnosis with Survival in Pancreatic Cancer Patients: A SEER-Medicare Analysis.
by: Christie Y Jeon, et al.
Published: (2015-01-01)

Survival associated with chronic obstructive pulmonary disease among SEER-Medicare beneficiaries with non-small-cell lung cancer
by: Shah S, et al.
Published: (2019-04-01)

Chemotherapy-Free Management of Follicular and Marginal Zone Lymphoma
by: Ollila TA, et al.
Published: (2021-05-01)

Rituximab treatment in a spondyloarthritis patient with low-grade follicular lymphoma: a case report
by: Patrícia Martins, et al.
Published: (2020-07-01)

Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)–Medicare investigation of treatment patterns and overall survival
by: Beebe-Dimmer JL, et al.
Published: (2016-10-01)

Treatment Patterns and Health Care Costs in Commercially Insured Patients with Follicular Lymphoma
by: Nathan H. Fowler, et al.

The cost of dying on Medicare: an analysis of expenditure data
by: House, Donald Reed
Published: (2005)

Healthcare costs and utilization for Medicare beneficiaries with Alzheimer's
by: Kuo Tzu-Chun, et al.
Published: (2008-05-01)

Switching Costs in the Market for Medicare Advantage Plans
by: Nosal, Kathleen Elizabeth
Published: (2012)

Comparative Study on Rituximab Combined with Chemotherapy and Single Chemotherapy for Diffuse Large B Cell Lymphoma
by: Ji-feng FENG
Published: (2015-06-01)

An Empirical Model of Medicare Costs: The Role of Health Insurance, Employment, and Delays in Medicare Enrollment
by: Yuanyuan Deng, et al.
Published: (2021-06-01)

Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia in Ukraine
by: Mandrik O, et al.
Published: (2015-08-01)